To include your compound in the COVID-19 Resource Center, submit it here.

Micromet, Serono deal

The companies amended a deal that gave SEO exclusive rights to MITI's adecatumumab (MT201) after

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE